secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001140361-26-012885
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Batoclimab TED Phase 3 misses endpoint; Roivant starts brepocitinib LPP trial; $4.3B cash
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities as of Mar 31, 2026: ~$4.3B.
- Repurchased 3,956,362 common shares for ~$109.7M in Q4 fiscal 2026.
- Immunovant's two Phase 3 studies of batoclimab in TED failed to meet primary endpoint of ≥2mm proptosis responder rate at Week 24.
- Priovant began Phase 2b/3 trial of brepocitinib in lichen planopilaris; first subjects enrolled Mar 2026.
- Brepocitinib NDA for dermatomyositis granted Priority Review; PDUFA target in Q3 calendar 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126012885/0001140361-26-012885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126012885/ef20069685_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-012885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer